One of the most important aspects of preparing travelers for destinations throughout the world is providing them with immunizations. Before administering any vaccines, however, a careful health and immunization history and travel itinerary should be obtained in order to determine vaccine indications and contraindications. There are three categories of immunizations for foreign travel. The first category includes immunizations which are routinely recommended whether or not the individual is traveling. Many travelers are due for primary vaccination or boosting against tetanus-diphtheria, measles-mumps-rubella, pneumococcal pneumonia, and influenza, for example, and the pre-travel visit is an ideal time to administer these. The second category are immunizations which might be required by a country as a condition for entry; these are yellow fever and cholera. The final category contains immunizations which are recommended because there is a risk of acquiring a particular disease during travel. Typhoid fever, meningococcal disease, rabies, and hepatitis are some examples. Travelers who are pregnant or who are infected with the human immunodeficiency virus require special consideration. Provision of appropriate immunizations for foreign travel is an important aspect of preventing illness in travelers.
GENERAL CONSIDERATIONS
For each traveler, it is important that a detailed travel itinerary, including the areas to be visited within each country, duration of stay, and medical and immunization history be obtained before any immunizations are given. A trip to Nairobi, Kenya, for a week's business conference does not present the same level of health risk as does prolonged travel for a malaria research project on the shores of Lake Victoria, even though both trips are to Kenya.
Vaccinations can be divided into those which are routinely recommended whether or not a person is traveling, such as tetanus-diphtheria, those which are required by countries as a condition for entry, such as yellow fever, and those which are recommended because of potential risk during travel, such as typhoid fever. Each immunization and its schedule for administration is listed in Table 1 .
It is important to distinguish between required and recommended vaccines. Required vaccines are those which one must have prior to being allowed to enter a country. Recommended vaccines are those which may be needed because infection could be acquired in the country of destination or in a particular location within that country. As an example, epidemic meningococcal disease only occurs in certain geographic areas of the world, and, if the traveler does not visit these areas, there is no need for that person to receive vaccine. On the other hand, typhoid fever occurs throughout the developing world but will be a risk to travelers only if they ingest untreated liquids or foods in areas of poor sanitation, such as may occur in rural areas and small villages. For those diseases which are transmitted by fecal contamination of the food and water supply, such as travelers' diarrhea, typhoid, poliomyelitis, cholera, hepatitis A, and giardiasis, the best prevention may be careful selection of food and liquids. If, however, there is unavoidable exposure to poor sanitation for more than two to three weeks, then it is reasonable to administer vaccines. For each of the potentially recommended vaccines, the physician must weigh the risk of disease acquisition with vaccine efficacy and side effects.
Vaccines are either inactivated viral or bacterial products, such as tetanus toxoid, typhoid, and rabies, or they are live, but attenuated, bacteria or viruses, such as yellow fever, oral poliomyelitis, and the new oral typhoid vaccine. Most parenteral vaccines, whether they are killed or attenuated, can be administered simultaneously at different sites, although cumulative side effects may preclude this procedure. If attenuated live viral vaccines cannot be given simultaneously, they should be given separated by one month. The administration of live vaccines may be contraindicated in certain groups of travelers, such as pregnant women [8] or immunocompromised hosts, including those with human immunodeficiency virus (HIV) infection [9] [10] [11] [12] . These issues will be discussed in the sections which follow, and specific contraindications are also listed in Table 1. Tables 2 and 3 give general guidelines for the administration of vaccines to pregnant or HIV-infected travelers, respectively. Infants and small children can be considered for the same immunizations as adults; however, the schedule and the administration may need to be altered [2, 5, 6] .
Prior to the administration of any biologic product, the manufacturer's full prescribing information should be consulted. For each vaccination, the type of vaccine, date of administration, dose, site, manufacturer, and lot number, as well as any untoward effects, should be recorded in the patient's record [13] . The pre-travel visit is an ideal time to update routinely recommended immunizations for both children and adults. The vaccine coverage for many travelers may be inadequate, putting them at risk for vaccine-preventable disease [14, 15] . At the International Traveler's Medical Service at the University of Connecticut Health Center, 43 percent of travelers were due for boosting against tetanus-diphtheria, 55 percent of those born in 1957 and later for a primary series or booster for measles, and 70 percent for poliomyelitis if their travel itinerary included a polio risk [14] . In addition, the wide age range of this group (4 percent were 12 years old and younger, and 13 percent were 65 years and older) provides the opportunity to bring children up to date on childhood immunizations and the elderly on influenza and pneumococcal vaccine. The immunizations listed below can be considered as routinely recommended. Although there has been a recent recommendation to include protection against hepatitis B as part of routine childhood immunizations, this vaccine will be discussed in the later section on immunizations recommended because of exposure [16].
1. Tetanus-Diphtheria Toxoids: Adults over the age of 50 constitute nearly 70 percent of tetanus cases in the United States. Most of these occurred in persons who were never immunized, received an incomplete primary series, or, rarely, had gone longer than ten years since their last booster [17, 18] . In addition, recent antibody studies also indicate that over 50 percent of adults may be susceptible to diphtheria [19] . For these reasons, all adults should have completed a primary series of tetanus-diphtheria and received boosters with the combined toxoids at ten-year intervals. Children under seven should receive the combined tetanus-diphtheriapertussis vaccine.
Some adult travelers may benefit from a booster of tetanus-diphtheria at a five-to ten-year interval, because they will not need either tetanus immune globulin or a booster if they sustain a tetanus-prone wound and have been boosted within five years [17] . Obtaining immunization before travel may be easier and safer than receiving an injection in a developing area, where the sterility of needles and vaccine storage conditions may be inadequate. 2. Measles: In the last few years, recommendations for measles immunization have been changed to include a two-dose schedule for the primary immunization of children and revaccination of selected older children and young adults [20, 21] . The reason for this change has been the dramatic increase in measles cases in the United States in 1989 and 1990, when the number of annual cases rose nearly tenfold to over 27,000 cases [22] . These cases primarily occurred in unvaccinated, inner-city children < 5 years of age, and in previously vaccinated school and college age individuals (five to 19 years). Measles which occurs in persons previously vaccinated is thought to be due to primary vaccine failure rather than to waning immunity.
Travel overseas may also constitute a substantial measles exposure to the unprotected traveler. From 1983 to 1988, 4 to 22 percent of measles cases (1, 478 cases) were epidemiologically linked within two generations to international travel [23, 24] , and about half of the initial cases were in returning Americans. In addition, during this period, 8 percent of all outbreaks of measles in the United States could be traced to an imported case [23, 25] .
All international travelers should be immune to measles [26] . Children traveling to high-risk areas where they are likely to be exposed at a young age can be vaccinated from six to 12 months with single-antigen (monovalent) measles vaccine, and from 12 to 15 months with the trivalent, measles-mumps-rubella vaccine. These children should be reimmunized at 15 months with the trivalent vaccine and should receive an additional dose at entry to school [20] .
Travelers [32] . Two of these, HibTITER<'t and PedvaxHIBS', are licensed for use in children beginning at two months of age, and one, ProHIB-ITV, is licensed for use at age 15 months and older. Each vaccine differs in the conjugated protein carrier used to stimulate T-cell responses, the size of the polysaccharide, the method of chemical conjugation, and the schedule of administration. All children, beginning at age two months, should receive protection against H. influenzae as part of their routine childhood immunizations. Those children older than two months and up to five years of age should receive the vaccine in a modified dosing schedule [32] . Immunization with the conjugate vaccines does not protect against the carrier protein, nor does it preclude immunizations with the other standard vaccines, such as diphtheria and tetanus toxoids and pertussis vaccine.
Required Immunizations
The vaccinations which may be required by a country prior to allowing the traveler to enter are yellow fever and cholera. A list of vaccine requirements by country is published annually by the Centers for Disease Control in Health Information for International Travel [2] . According to international health regulations, required vaccinations must be recorded in the document "International Certificate of Vaccination" [33] [36] . In recent years, jungle yellow fever in non-human primates has been reported from Trinidad and Tobago [37] . Areas in Africa and South America where infection could occur, but where cases are not being reported, are called "endemic zones."
The yellow fever vaccine should be given to persons who are traveling to or living in "infected" areas, and to persons who visit rural areas of countries in the "endemic zones" for yellow fever [38] . Some countries which do not lie in the endemic zones, particularly those in Asia, may require immunization for persons entering from an area where yellow fever is occurring. The vaccine is given only in approved vaccination centers because of its requirement for cold storage and viability for only 60 minutes after reconstitution. One can call state or local health departments to identify these centers. If cholera and yellow fever vaccines are both given, they should ideally be separated by a minimum of three weeks, since simultaneous administration may interfere with the antibody response to each vaccine [39] . Immune globulin does not interfere with the response to yellow fever vaccine.
2. Cholera: The outbreak of cholera which began in January of 1991 in western South America and has spread to Mexico, Central America, and other areas of South America, has captured world attention [40] . This outbreak emphasizes what can happen when an infectious agent such as Vibrio cholerae is introduced into a susceptible population. Although a few cases have occurred in tourists to these areas, the overall risk of cholera remains extremely low for those who exercise caution in food and water sanitation [41, 42] . The poor vaccine efficacy, combined with its uncomfortable side effects, make vaccination infrequently indicated [43] . In accordance with this information, in 1988 the World Health Organization no longer recommended cholera immunization for international travel. No country requires administration of cholera vaccine before direct travel from the United States, and fewer than ten countries require vaccination before entry from a country reporting cholera, such as entering Pakistan from India or Tanzania from Kenya [2] .
Persons who may be considered for vaccination are those who will work and live in highly endemic areas with poor sanitary conditions and persons with impaired gastrointestinal defense mechanisms. One dose, properly recorded and given at least six days before travel, is satisfactory for entry into countries requiring vaccination. A letter of medical contraindication should suffice for those travelers who either cannot or do not wish to receive vaccine. Studies continue on new oral preparations of vaccine [44] .
Immunizations Recommended Because ofExposure 1. Typhoid: The risk of typhoid fever varies by destination. In a retrospective review of typhoid cases in the United States, it was estimated that 0.1 per one million travelers to Northern Europe compared with over 100 per one million travelers to India, Pakistan, or Peru will acquire typhoid fever [45] . Two vaccines are currently available in the United States for protection: the older inactivated vaccine and a recently released attenuated oral vaccine [46] . A third vaccine, which has not yet been licensed in the United States, contains purified Vi capsular polysaccharide of S.
typhi and has approximately 70 percent efficacy over one to two years [47, 48] .
The attenuated oral vaccine uses the Ty 21a mutant, of S. typhi that produces enough lipopolysaccharide to be immunogenic but does not undergo sustained replication [49] . In a large-scale field trial in Chilean school children, it had an efficacy of 67 percent [50] , which is similar to that of the older heat-phenolinactivated parenteral vaccine (50 percent to 70 percent). The attenuated vaccine, however, is easier to give because of its oral route of administration, is better tolerated by the patient, and can be completed within a week of starting the procedure. Strict instructions need to be given to recipients to assure vaccine refrigeration and compliance with each dose given on alternate days for a total of four doses [51] .
Typhoid vaccine should be given to travelers visiting areas endemic for typhoid fever, where fecally contaminated food and water are likely to be ingested [52] . Travelers to areas where Salmonella typhi is resistant to antimicrobial agents should also be considered for vaccination. Although it is not stated in the product insert, the oral typhoid vaccine may interfere with the response to oral polio vaccine, suggesting that their administration should be separated by at least two weeks [53] . It may also be best to delay initiation of anti-malarial prophylaxis until a week after completing oral typhoid vaccine because of the theoretical antimicrobial effect of anti-malarials [53] .
2. Meningococcal Disease: Several areas of the world have epidemic meningococcal disease, which poses a low, but potential, risk to international travelers [54] . Trekkers in Nepal, travelers to the New Delhi region of India, to Kenya or Tanzania, religious pilgrims to Saudi Arabia, and long-term visitors to sub-Sahara Africa should be considered at potential risk and vaccinated [54, 55] . The [56] . Prophylactic antibiotics may be indicated for the traveler with a definite exposure.
4. Tuberculosis prevention: A traveler to the developing world is at risk for tuberculosis if that person has prolonged contact with respiratory droplets from infected persons in a closed setting. The approach to these travelers should not be vaccination with the bacillus of Calmette and Guerin (BCG) vaccine, but pre-and post-travel tuberculin skin testing [57] . For those rare children who will have unavoidable exposure to tuberculosis and for whom other preventive measures such as prophylactic isoniazid have failed or cannot be used, BCG vaccine may be considered.
Poliomyelitis:
The decade of the 1990s holds the hope of elimination of polio from the Americas [58] . Already 30 percent of the world's population lives in polio-free areas. Polio virus remains endemic throughout many areas of the developing world, however, particularly in Asia and Africa, and, if vaccine coverage falls, poliomyelitis can occur in the developed world as well [59] . The risk for poliomyelitis for an international traveler is extremely small [60] . In the United States, of 138 cases of paralytic polio from 1973 to 1984, only 13 cases were imported [61] . Nevertheless, all travelers to areas of risk with exposure to poor food and water sanitation should be immunized to polio.
There are two vaccines for protection against polio: the oral polio vaccine (OPV; Sabin, live attenuated trivalent vaccine), and the inactivated polio vaccine of enhanced potency (eIPV). The eIPV has replaced the conventional inactivated polio virus vaccine (Salk vaccine). Primary immunization of children in the United States is accomplished with OPV [62] . Because rare cases of paralytic polio are associated with OPV, it is usually not given as primary vaccination in adults. The risk of paralysis in first-time recipients of OPV and contacts of recipients is approximately one case per 520,000 doses, and, for all subsequent doses, one case per 12.3 million doses [61] . Contacts of vaccine recipients accounted for nearly 60 percent of cases. These contacts were usually unimmunized or inadequately immunized parents or relatives of a child who received OPV.
Primary vaccination for persons 18 years or older should be done with eIPV [63] . If at least two doses of eIPV cannot be given before protection is required (less than four weeks before departure), a single dose of either oral polio vaccine or eIPV can be given. If a person has completed or started a primary series with either OPV or an inactivated polio vaccine, either oral polio vaccine or eIPV may be used to complete the series or to boost the patient's response. It is recommended that persons who have completed a primary series receive a one-time booster if traveling to an area of risk. Both oral polio vaccine and eIPV provide long-term immunity and may be given with immune globulin. 6 . Japanese B Encephalitis: The risk of Japanese B encephalitis to the international traveler is extremely low; however, rare fatalities have occurred and have prompted interest in vaccination [64] . Japanese B encephalitis is a mosquitotransmitted flavivirus infection of the central nervous system, and occurs in temper-ate zones (China, Japan [little to no risk], Korea, the lowlands of Nepal, Burma, Bangladesh, Kampuchea, Laos, northern India, and Thailand, and the eastern part of the former Union of Soviet Socialist Republics) from June through September, and in tropical zones (southern India and Thailand, Taiwan, Indonesia, the Philippines, Malaysia, Sri Lanka, and Singapore), throughout the entire year [65] . Over 98 percent of infections are unapparent, but among those patients with symptomatic disease, the fatality rate is approximately 20 percent, with a high morbidity in survivors [66, 67] . Clinical disease occurs primarily in young children and adults more than 65 years of age.
Beginning in May 1983, a monovalent inactivated vaccine, purified from mouse brain (BIKEN, The Research Foundation for Microbial Diseases, Osaka University, Japan), was studied under an investigational new drug exemption in the United States. The vaccine was immunogenic and well-tolerated in a three-dose schedule [68] , and in the Far East it has been safe and effective, based on years of use [69] . Nevertheless, because of concern about liability protection, the vaccine was withdrawn from the United States in July of 1987. Efforts are under way, by the Centers for Disease Control, Connaught Laboratories, Inc., the Food and Drug Administration, and the U.S. Army, to obtain a product license.
Persons are at risk for Japanese B encephalitis if they are traveling in endemic areas for more than three weeks and will have rural exposure in areas of rice and pig farming during the summer months [66] [67] [68] . If they will not have such exposure, but are planning prolonged residence in endemic countries, they should also be vaccinated. Until the vaccine is licensed in the United States, travelers should obtain vaccine in the country of destination. All travelers should exercise prevention measures against the Culex mosquito, the vector for transmission.
7. Rabies: Although the risk of rabies during travel is very low, all travelers should be informed about it because animal rabies remains endemic in many areas of Latin America, the Far East, and Africa. Those countries which report no cases of rabies are listed in Health Information for International Travel [2] . Dog rabies continues to be the major reservoir for transmission to humans, with eight of ten cases of rabies in travelers from 1975 to 1984 associated with dog bites [70] . Some of the dogs had been vaccinated against rabies in the foreign country, raising important questions about the type and method of delivery of vaccine.
The first step after being bitten by a potentially rabid animal is thorough cleansing of the wound with soap and water. If the traveler has not received pre-exposure rabies prophylaxis, the individual should then seek immediate post-exposure prophylaxis. Pre-exposure prophylaxis does not eliminate the need for prophylaxis after exposure, but does make the treatment easier by requiring fewer doses of vaccine and eliminating the need for human rabies immune globulin. Travelers who should be considered for rabies vaccine are those who will live for one month or more in an area where rabies is a constant threat [71] . The primary vaccine available in the United States is the human diploid cell rabies vaccine (HDCV). An absorbed vaccine adapted to fetal rhesus lung tissue is available to residents of Michigan from the Michigan Department of Public Health. HDCV can be administered either intradermally or intramuscularly [71] . If vaccination cannot be completed before initiating malaria chemoprophylaxis, then the intramuscular route is necessary. The simultaneous administration of chloroquine for malaria prophylaxis has been shown to decrease the immune response to intradermally administered vaccine [72] . Although this phenomenon has not been studied with mefloquine, it would seem prudent to avoid the intradermal route when mefloquine is being given. As with other intramuscular vaccines for adults, intramuscular rabies vaccine should be given in the deltoid muscle in order to assure adequate absorption.
8. Hepatitis Prophylaxis: Hepatitis A: The highest risk for hepatitis A occurs with travel to rural areas with poor hygiene, outside the usual tourist routes [73] . Because hepatitis A has occurred in travelers on standard tourist itineraries, however, most travelers should be offered protection. Hepatitis A in travelers who have not received prophylaxis occurs from one to ten times per 1,000 travelers for a two-to three-week stay in the developing world [74] .
Prevention of hepatitis A is achieved with immune globulin (IG), a sterile preparation of purified antibodies, primarily of IgG type, which contains high titers against hepatitis A. IG prepared in the United States has not transmitted any viral infections, including hepatitis B or HIV [75] . The protection conferred by IG is short-lived, two to three months for the standard dose (0.02 ml/kg) and four to six months for the higher dose (0.06 ml/kg). For those travelers who remain overseas for more than six months, regular administration (at four-to six-month intervals) is necessary. Pre-travel anti-hepatitis A IgG antibody screening may be helpful for travelers who are frequent visitors to the developing world, or who are likely to have acquired hepatitis A in the past, and would prefer not to get the intermittent injections ofIG. Persons who may have acquired hepatitis A previously are those over the age of 50, those who were born or lived for a prolonged time in the developing world, and those with a history of hepatitis [76] . Human trials are currently under way with whole-cell inactivated hepatitis A vaccines, and preliminary studies have examined live, attenuated, and recombinant vaccines [77, 78] . Killed, whole-cell vaccines seem most promising [79] .
Hepatitis B: Hepatitis B is a risk for short-or long-term travelers with exposure to blood or body fluids, and for long-term travelers ( .6 months) to countries with a high seroprevalence of hepatitis B surface antigen carriage. Those who are at risk because of exposure are usually physicians, nurses, other health care workers, and laboratory technicians, and those who are likely to have sexual exposure [73] . Regions with a high prevalence (5 percent to 20 percent) of hepatitis B carriage include China, southeast Asia, sub-Sahara Africa, the Amazon basin, and parts of the Middle East.
Vaccines which contain recombinant hepatitis B surface antigen have replaced the original plasma-derived vaccine in the United States. Hepatitis B vaccines should be administered intramuscularly in the deltoid in order to assure an optimal response. One vaccine can be given in a four-dose schedule, with the first three doses given over two months (Table 1 ). This timing can allow a more rapid achievement of immunity prior to travel for those who might require it. To date, vaccine boosting has not been recommended for the non-compromised host [16, 73] . Vaccination against hepatitis B will protect the traveler against delta hepatitis, since this agent requires active hepatitis B replication [80] .
Enterically Transmitted Hepatitis: A new form of enterically transmitted non-A, non-B hepatitis has been recognized in Mexico, the Indian subcontinent, and Africa over the past decade [81] . Several outbreaks [82] 
IMMUNIZATION OF SPECIAL GROUPS The Pregnant Traveler
During the pre-travel evaluation of the pregnant traveler, one needs to consider the likelihood of acquiring a vaccine-preventable disease during the trip, the consequences of this disease to the mother and her unborn child, and the potential risks and benefits of vaccination to both mother and child. There are several sources which help to assess these factors [2] [3] [4] 7, 8] . While many vaccines may be safely tolerated during pregnancy, it is best to avoid vaccination altogether, if possible, or at least to delay it until after the first trimester. [12, [86] [87] [88] [89] . Finally, access to sophisticated medical care may be limited, increasing the potential morbidity from an HIV-associated illness such as Pneumocystis carinii pneumonia.
The two issues of efficacy and safety also apply to immunizing HIV-infected travelers [9] [10] [11] [12] . Many vaccines are less immunogenic in HIV-positive individuals, and response rates decline as HIV infection advances [90] . Moreover, there are theoretical risks of progressive, disseminated infections with attenuated live vaccines, as has occurred with BCG and vaccinia virus [91, 92] . In contrast, the morbidity from measles outweighs the theoretical risk of vaccine toxicity [93, 94] . Each of these issues needs to be considered and discussed with the HIV-infected traveler prior to vaccine administration. Table 3 provides guidelines for the immunization of asymptomatic HIV-infected travelers and those with symptomatic infection and AIDS. It may be reasonable to determine the CD4 lymphocyte count prior to vaccine administration, both to predict the potential response to vaccination and to assess the potential risk of the vaccine [12] .
1. Bacterial Vaccines: The inactivated bacterial vaccines can be given safely. Tetanus-diphtheria should be given by the routine schedule. Because HIV-infected persons are at increased risk from infections with encapsulated bacteria, they should be protected with both pneumococcal and Hemophilus influenzae vaccines. Meningococcal vaccine should be given to those who travel to areas of risk. Although there is no data on the safety of the live, attenuated vaccine against S. typhi, it would be cSafety is unknown, and vaccination should be avoided until further study. Source: Adapted from [7] prudent to avoid this type and to give the killed, whole-cell preparation. The minimal risk for cholera and poor vaccine efficacy do not justify routine vaccination. Some AIDS patients may be at higher risk for enteric organisms because of lowered gastric acidity, however, and for these travelers at risk for cholera, vaccination may be considered [95] . BCG vaccination is unnecessary, may be dangerous, and should be avoided.
2. Viral Vaccines: Inactivated viral vaccines should be used for protection against viral illness. Influenza immunization should be given annually to HIVinfected patients. Protection against polio should be achieved with eIPV rather than with OPV because of the risk of vaccine-associated paralysis. Because of the high incidence of hepatitis B infection in the HIV-infected population, pre-vaccination screening for hepatitis B antigen and antibody should be done. If rabies prevention is needed, the intramuscular route of administration should be used in order to assure the maximum immune response. There is no information on safety or efficacy of Japanese B encephalitis vaccine in immunocompromised hosts. Immune globulin may be administered safely.
Although yellow fever vaccine has been demonstrated to be very safe after millions of doses, rare cases of vaccine-associated encephalitis have occurred. Because of the theoretical risk of encephalitis in immunosuppressed patients, vaccination should be avoided in symptomatic HIV-infected patients. These travelers should also avoid areas of the world where outbreaks of yellow fever are occurring [36, 38] . If exposure is unavoidable for the symptomatically infected traveler, a letter of medical contraindication should be provided, and the individual should be instructed on rigorous avoidance of mosquitoes. For the asymptomatic HIV-infected traveler, vaccination can be offered after the risks are explained. Because the immune response may be diminished, it may be wise to check post-vaccination titers.
The consequences of measles in unprotected HIV-infected persons may be severe [94] . Because of the severity of the illness and the safety of vaccination, HIV-infected travelers at risk for measles should be immunized. This precaution should be done routinely for asymptomatic patients and considered for at-risk patients with symptomatic HIV infection.
